Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASCINATE-N: Precision Neoadjuvant Therapy in Operable Breast Cancer
NCT05582499Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2022
- Primary completion
- Dec 2027
- Modality
- Irreversible Covalent Inhibitors, Antibody-Drug Conjugates (ADCs), Targeted Protein Degraders (TPDs)
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib, pyrotinib, trastuzumab rezetecan, adebrelimab, camrelizumab in breast cancer, sponsored by Fudan University. Started Nov 2022; status: recruiting.
02
Drugs
dalpiciclibpyrotinibtrastuzumab rezetecanadebrelimabcamrelizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05582499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582499.